


Evaluating Healthcare Technologies

Mirella Marlow MA MBA, Programme Director
29 Feb 2016

What do decision makers need to know about new technologies?



NICE medtech value proposition options

Clinical performance	Better		Non-inferior
Cost	Higher		Less overall
Evaluation method	Cost effectiveness (QALY)		Cost consequences
NICE guidance programme	Technology Appraisals Programme (TAP)	Diagnostics Assessment Programme (DAP)	Medical Technologies Evaluation Programme (MTEP)
Technologies	✓ Devices	✓ Diagnostics	✓ Devices ✓ Diagnostics

Population Intervention Comparator Outcomes (PICO)

- Can you complete a PICO for your product?

Population	Diagnosis or degree of illness, setting, age, co-morbidity
Intervention	Your product
Comparator	Current standard of care informed by guidelines, expert opinion
Outcomes	What are the outcomes you need to generate evidence on in order to demonstrate your product's value? <ul style="list-style-type: none">• Clinically meaningful• Outcomes showing impact on resource utilisation

Pomfrett C.J.D, Campbell B, Pugh P.J, Campbell M, Marlow M. Medical Technologies Evaluation II: catalysing the development of primary clinical evidence for promising technologies. HTAI Bilbao 2012




Fig 1. Indirect research facilitation. Yellow stages are facilitated by NICE.

Accelerated Access Review

The Accelerated Access Review aims to speed up access to innovative drugs, devices and diagnostics for NHS patients.

Innovator focus

Authored article

Six questions every health innovator should ask

From: [Accelerated Access Review](#) and John Jeans, Accelerated Access Review's expert on medtech

Written on: 26 October 2015

First published: 26 November 2015

Asking the right questions early on is important if innovations are to be adopted across the NHS, argues John Jeans.

AAR and NICE

- Coordination and support for the National Innovation Partnership
- Transformed NICE Technology Evaluation Pathways
- Mechanisms for Managed Access and budget control embedded in NICE
- The NICE Digital offer
- Continuation of the NICE Implementation Collaborative (NIC) with a revised remit (complex medtech and dx)
- Horizon Scanning and topic selection

NICE Office for Market Access

www.nice.org.uk/oma

Home > About > What we do

Office for Market Access



Expert advice for the life sciences industry

We'll help you understand:

- NICE processes
- How to work with NICE to achieve your aims
- How NICE links with different parts of the system
- The Early Access to Medicines Scheme (EAMS) and our role supporting it - [read the process](#)

[Get in touch to find out more](#)